BEDFORD, Mass., June 30, 2015 (GLOBE NEWSWIRE) -- ConforMIS, Inc. announced today the pricing of its initial public offering of 9,000,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts. All of the shares in the offering are being sold by ConforMIS. In addition, ConforMIS has granted the underwriters an option to purchase up to 1,350,000 additional shares of common stock at the public offering price, less the underwriting discount. ConforMIS' common stock has been approved for listing on the NASDAQ Global Select Market and is expected to begin trading under the symbol "CFMS" on July 1, 2015. The offering is expected to close on July 7, 2015, subject to customary closing conditions.
J.P. Morgan and Deutsche Bank Securities are acting as joint book-running managers for the offering. Wells Fargo Securities, Canaccord Genuity and Oppenheimer & Co. are acting as co-managers.
This offering is being made only by means of a prospectus. A copy of the prospectus may be obtained from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204; or Deutsche Bank Securities Inc., Attention: Prospectus Group, 60 Wall Street, New York, NY 10005-2836, or by email to email@example.com, or by telephone at +1 (800) 503-4611.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.
ConforMIS is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped, or customized, to fit each patient's unique anatomy. ConforMIS offers a broad line of customized knee implants designed to restore the natural shape of a patient's knee.
CONTACT: Investor Contact: Paul Weiner firstname.lastname@example.org (781) 345-9001 Media Contacts: Bill Berry Berry & Company Public Relations Bberry@berrypr.com (212) 258-8881 Lynn Granito Berry & Company Public Relations Lgranito@berrypr.com (212) 253-8881